Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493109 | 0.93 | MMP2 (0.33) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL4489808 | 0.92 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL13712260 | 0.92 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL4491594 | 0.91 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL4495276 | 0.91 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL13712254 | 0.91 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL13712257 | 0.91 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL4490615 | 0.90 | MMP2 (0.33) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL4493945 | 0.90 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 | |
| SCHEMBL13712266 | 0.90 | MMP2 (0.31) | MMP2MMP13RECQLLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | MMP2 4305/4885MMP13 3395/4885RECQL 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.